Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SLS Relative to the S&P 500

SLS Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the SELLAS Life Sciences Group, Inc. (NASD:SLS) seasonal charts above shows that a Buy Date of August 17 and a Sell Date of November 5 has resulted in a geometric average return of 0.77% above the benchmark rate of the S&P 500 Total Return Index over the past 14 years. This seasonal timeframe has shown positive results compared to the benchmark in 7 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 14 years by an average of 100.77% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Its product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The company is also developing GFH009, a small molecule, CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai) Inc, for all therapeutic and diagnostic uses in the world outside of Greater China.

To download SLS seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SLS